Boston Scientific stock: Leerink cuts target to USD 55.00 from USD 60.00

Published on 10/20/2026 at 16:38 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Second-quarter 2026 revenue reached USD 5.44 billion, up 7.50 percent year over year. Boston Scientific stock costs EUR 40.78 on October 20, 2026.

Leerink target reduction

Leerink Partners cut its Boston Scientific target from USD 60.00 to USD 55.00 on October 12, 2026.
Second-quarter 2026 revenue rose 7.50 percent year over year to USD 5.44 billion.
Boston Scientific stock cost EUR 40.78 at Lang & Schwarz on October 20, 2026 at 4:32 p.m. CEST.
The next quarterly report is scheduled for October 28, 2026.

Aquarell der Bostoner Skyline mit Bürotürmen, die sich im Charles River spiegeln — Boston Properties US1011371077 als aquarellierte Bostoner Skyline mit Bürotürmen am Charles River, Illustration mit AI erstellt.

Boston Scientific (ISIN US1011371077) faces a lower analyst valuation after MarketBeat reported on October 12, 2026 that Leerink Partners cut its Boston Scientific target from USD 60.00 to USD 55.00. The new target lies 19.83 percent above the NYSE price of USD 45.90 at 10:37 a.m. ET on October 20, 2026. At Lang & Schwarz, the stock stood at EUR 40.78 on October 20, 2026 at 4:32 p.m. CEST.

Quarterly growth remains measurable

Boston Scientific reported second-quarter 2026 revenue of USD 5.44 billion, up 7.50 percent from USD 5.06 billion in the same quarter a year earlier. Adjusted earnings per share reached USD 0.86, compared with USD 0.75 a year earlier, according to Markets Insider on July 30, 2026. The figures show that the company entered the second half with revenue growth, even as analysts marked down their valuation assumptions.

Price position stays wide

On the NYSE, Boston Scientific last traded at USD 45.90 on October 20, 2026 at 10:37 a.m. ET. Its 52-week range was USD 41.39 to USD 105.65, while the market capitalization stood at USD 66.5 billion on the same date. Trading volume reached 3,487,296 shares at that time.

What comes before the next report

Boston Scientific is scheduled to report third-quarter 2026 results on October 28, 2026 before the US market opens, with an earnings call at 8:00 a.m. ET, according to MarketBeat. The published estimate is USD 5.10 billion in revenue and USD 0.7460 in earnings per share. The prior-year quarter produced USD 5.07 billion in revenue and USD 0.75 in earnings per share.

The lower target from Leerink contrasts with the recent operating figures. A separate September 21 analyst note from Oppenheimer cut its target from USD 85.00 to USD 65.00 while retaining an Outperform rating, citing cybersecurity disruption and competitive pressure in left atrial appendage closure and electrophysiology, as Yahoo Finance reported. That gives investors a concrete test for the October report: whether the next quarter can preserve growth while the company updates its outlook.